Delayed Nausea and Vomiting in Patients With Colorectal Cancer Receiving Oxaliplatin
N/A
RATIONALE: Learning how often patients experience nausea and vomiting after...
Status
Completed
Location
Beth Israel Medical Center - Philipps Ambulatory Care Center
Start Date
2005-06
Trial ID
NCT00729677
Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer
PHASE2
RATIONALE: Monoclonal antibodies, such as cetuximab and bevacizumab, can bl...
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
PHASE2
FC-6 is a Phase II, multi-center clinical trial for patients with unresecta...